Mangoceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports financing and related corporate actions effective April 5, 2024. It is not a periodic financial report and does not provide current revenue, profit, cash flow, margin, debt, or liquidity results. Mangoceuticals is an emerging growth company with common stock traded on Nasdaq under MGRX.
Financing and Key Financial Terms
| Transaction | Key terms |
|---|---|
| Series B preferred stock and warrants | Up to 1,500 shares of Series B Convertible Preferred Stock for aggregate consideration of $1.65 million, plus warrants to purchase up to 3.3 million common shares for $1.5 million. |
| Initial closing | 500 Series B shares and warrants for aggregate proceeds of $500,000 on April 5, 2024. |
| Additional closings | A second closing of $250,000 and a third closing of $750,000 are subject to conditions, including stockholder approval and effectiveness of the resale registration statement. |
| Equity line of credit | Purchaser committed to purchase up to $25 million of common stock over a two-year period, subject to conditions. The Company issued 1 million commitment shares and is not required to draw on the facility. |
The Series B Preferred Stock has an initial stated value of $1,100 per share and a 10% annual cumulative dividend, payable when authorized and declared. Dividends may be paid in cash, common stock, or by increasing the stated value. The preferred stock has a liquidation preference equal to stated value plus accrued dividends and generally has no voting or redemption rights, subject to specified provisions.
Conversion is based on the lesser of $0.40 or 90% of specified trailing VWAP measurements, subject to a $0.035 floor price and anti-dilution adjustments. The initial 500 shares could result in a maximum of approximately 15.7 million common shares upon full conversion at the floor price, excluding in-kind dividends. The warrants have a $0.26 exercise price, become exercisable October 4, 2024, and expire five years thereafter. Full exercise would result in 3.3 million additional common shares.
Material Changes and Dilution
- The Company issued 500 Series B Preferred shares, warrants for 3.3 million common shares, and 1 million commitment shares at the initial closing.
- Up to 50 million common shares have been reserved for conversion of the preferred stock and exercise of the warrants.
- Before stockholder approval, issuances under the financing documents and related transactions are generally limited to 19.99% of pre-transaction outstanding common shares, or 4,721,538 shares.
- Stockholder approval is required to waive the exchange cap and, if necessary, increase the authorized common shares. The Company must hold a stockholder meeting within 30 days of the initial closing and additional meetings at least semi-annually if approval is not obtained.
- The financing creates substantial potential dilution, including variable conversion pricing, anti-dilution protection, warrant repricing provisions, and the $25 million equity line.
Outlook, Risks, Contingencies, and Unusual Items
- The Company must file resale registration statements for the financing securities generally within 30 days and satisfy specified effectiveness deadlines. Failure to meet registration obligations may trigger liquidated damages.
- The preferred stock includes restrictive covenants, protective provisions, ownership limitations, and events of default. Following an event of default, the dividend rate may increase to 18%, stated value may increase by 17.5%, and the conversion price may be reduced, subject to the floor price.
- The Company is restricted from certain equity issuances, variable-rate transactions, repurchases, dividends on junior securities, and specified affiliate transactions while the preferred stock remains outstanding.
- The Purchaser has participation rights in subsequent financings for 18 months and may purchase an additional $1 million of Series B Preferred Stock at a $1.1 million stated value before the applicable option deadline.
- The equity line requires an effective resale registration statement and other conditions, including a minimum common-stock closing price above $0.15 for an advance notice. The Company has no obligation to sell shares under the facility.
- The securities were issued or are expected to be issued in reliance on private-placement exemptions under Section 4(a)(2) and/or Regulation D and are subject to transfer restrictions.
- Jacob D. Cohen was appointed Secretary on April 5, 2024. The filing was signed April 11, 2024.
Investor Verification Checklist
- Verify whether the second and third financing closings occurred and the amount of cash actually received.
- Confirm the status and effectiveness of the SPA and ELOC resale registration statements.
- Review the Company’s stockholder approval results and any increase in authorized common shares.
- Reconcile the outstanding common shares, reserved shares, preferred-stock conversion exposure, warrant shares, and commitment shares.
- Monitor potential dilution from the variable conversion price, floor price, anti-dilution provisions, warrant repricing, and equity-line draws.
- Review subsequent filings for registration-related liquidated damages, defaults, conversions, redemptions, or additional financing.
- Assess the Company’s ability to meet preferred-stock dividends, registration obligations, and other financing covenants; this filing does not provide a clear current liquidity value.